secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOREGENX, INC. (BRGX)
CIK:        0001593184
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001683168-24-001917
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 3.02, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioRegenx completes reverse merger with Findit; new board, name change effective March 8, 2024
--------------------------------------------------------------------------------

- BioRegenx merged into Findit (OTC Pink: FDIT); surviving entity renamed BioRegenx, Inc.
- Former BioRegenx holders received 851,977,296 common + 3,800 Series A preferred shares, representing 90% voting control.
- Prior shareholders retired 98.47% voting control preferred shares and 172,197,602 common shares.
- New officers appointed: William Resides CEO/interim CFO; board expanded to 7 directors.
- Authorized common stock increased to 1.5B shares; press release notes GlycoCheck device ($22k-$32k system) and DocSun 40% revenue share, $10/vehicle license fee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/0001683168-24-001917-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593184/000168316824001917/bioregenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-001917

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer